Skip to content

Stereotactic radiotherapy of localized prostate cancer with daily online adaptive radiotherapy planning: a single-arm prospective interventional observational study (PCa SBRT Study)

Stereotactic radiotherapy of localized prostate cancer with daily online adaptive radiotherapy planning: a single-arm prospective interventional observational study (PCa SBRT Study) - PCa SBRT Study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037100
Enrollment
50
Registered
2025-09-25
Start date
2026-03-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: A registry is to be created of patients with locally confined (< cT3 and cN0) prostate cancer or oligometastasis who are to undergo curative-intent radiation therapy using stereotactic radiat

Sponsors

Klinik für Strahlentherapie und Radioonkologie
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Informed consent available for the planned study and, if applicable, biobank - Karnofsky performance score = 60 - confirmed localized (< cT3 and cN0) prostate carcinoma or oligometastasis - curative-intended radiotherapy with suitability for SBRT - IPSS (at time of inclusion in the study) < 13 - PACE-B criteria all fulfilled: -- cT1 or cT2 primary -- Gleason score max. 3+4 -- PSA < 20 ng/mL at the start of therapy

Exclusion criteria

Exclusion criteria: - polymetastasis - previous irradiation in the pelvic area - known HIV or hepatitis infection (for biobank) - incapacity to give informed consent

Design outcomes

Primary

MeasureTime frame
- Creation of a prospective registry with data from patients (longitudinal recording of e.g. success of therapy, acute and chronic side effects, quality of life, dosimetry, costs, biomarkers ...) who receive stereotactic radiotherapy for localised prostate cancer - Gaining knowledge and deriving new research hypotheses

Secondary

MeasureTime frame
- overall survival, progression-free survival, locoregional recurrence, biochemical failure-free survival, disease-free survival, distant metastasis-free survival - clinician reported outcome - patient reported outcome and symptoms - laboratory chemical changes during the course of therapy (PSA dynamics, PSA bounce effect) - Correlation between side effects and dosimetric endpoints, radiotherapy plans, imaging - Recording of decision regret - Absolute treatment costs (for patients and society)

Countries

Germany

Contacts

Public ContactEleni Gkika

Klinik für Strahlentherapie und Radioonkologie

eleni.gkika@ukbonn.de+49 228 287 10352

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026